Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Caplacizumab resistance in immune thrombotic thrombocytopenic purpura is associated with a von Willebrand factor A1 domain missense variant.

Journal of thrombosis and haemostasis : JTH - 1 May 2026

Thomas Mari, Buckle Imogen, Constantinescu-Bercu Adela, De Groot Rens, McCann Sabina, Scully Marie

Abstract excerpt

Caplacizumab has been shown to reduce time to platelet normalization, reduce thrombotic thrombocytopenic purpura (TTP) exacerbations, and prevent refractory acute disease. We report the first case of caplacizumab "resistance" in a patient with immune TTP with a failure of suppression of in vivo von Willebrand factor (VWF) activity by the drug and persistence of VWF-mediated platelet capture in a flow-based in...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to ADAMTS13 Protein
Share to Binding Sites

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drug Resistance

Share to Mutation, Missense

Share to Purpura, Thrombotic Thrombocytopenic

Share to Single-Domain Antibodies

Share to Treatment Failure

Share to von Willebrand Factor

Source

Identifiers

PMID: 41692094
DOI: 10.1016/j.jtha.2026.01.023

Genes

VWF

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 8 closest

Caplacizumab resistance in immune thrombotic thrombocytopenic purpura is associated with a von Willebrand factor A1 domain missense variant.PMID 41692094Read ↗

The role of gene polymorphisms in the susceptibility and therapeutic response of chronic immune thrombocytopenic purpura.Semantic proximity Read ↗

Platelet-type von Willebrand disease: a rare, often misdiagnosed and underdiagnosed bleeding disorder.Semantic proximity Read ↗

An update on the pathogenesis and diagnosis of thrombotic thrombocytopenic purpura.Semantic proximity Read ↗

Analysis of clinical factors in first diagnosis of immune thrombotic thrombocytopenic purpura with report of 6 casesSemantic proximity Read ↗

Identification and functional characterization of a novel F5 mutation (Ala512Val, FVB onn ) associated with activated protein C resistance.Semantic proximity Read ↗

Genetics of thrombotic thrombocytopenic purpura: systematic review in immune and congenital thrombotic thrombocytopenic purpura.Semantic proximity Read ↗

Natural variants of von Willebrand factor R1205 causing von Willebrand disease with accelerated von Willebrand factor clearance: <i>in silico</i> docking models and energetics of the interaction with both LRP1 and GpIb A1 domainSemantic proximity Read ↗

Functional analysis of three recombinant A1-VWF domain mutants in comparison to wild type and plasma-derived VWF facilitates subtyping in type 2 von Willebrand disease.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.